Theacrine
Caffeine's cousin, priced on family resemblance and two small trials of how people feel.
D+
Evidence grade
D
Worth it
$15-25/month
Typical cost
DoseStudies used 200 to 300 mg/day, often in combination products that confound attribution. Half-life appears longer than caffeine's. Nothing about dose-response in humans is established beyond those two small programs.
BasisTheacrine is caffeine's chemical cousin with a fraction of its evidence: a couple of small, interested, short trials measuring how people say they feel, and nothing on performance, cognition, or outcomes.
Theacrine is a purine alkaloid from kucha tea, structurally adjacent to caffeine, sold as a smoother, longer, non-habituating stimulant, usually inside pre-workout and focus formulas. We grade Theacrine D+ on evidence and D for worth-it at about $15-25 per month.
What it does
Theacrine is a purine alkaloid from kucha tea, structurally adjacent to caffeine, sold as a smoother, longer, non-habituating stimulant, usually inside pre-workout and focus formulas.
What the research says
Subjective energy and focus improved in one small industry-linked trial program; habituation claims rest on a single study
Evidence: weak. Kuhman 2015 (60 adults, seven days) reported improved subjective energy, focus, and concentration at 200 mg/day versus placebo, with industry involvement. An eight-week study (Taylor 2016) reported no tolerance development, the source of the 'caffeine without habituation' claim: one small study, never independently replicated. Objective performance outcomes, in exercise or cognition, are essentially untested.
Theacrine is caffeine's chemical cousin with a fraction of its evidence: a couple of small, interested, short trials measuring how people say they feel, and nothing on performance, cognition, or outcomes. It may yet prove useful; its current price and prominence are set by analogy, not data. D+ until someone runs a real trial.
Is it worth it?
Evidence (D+) sits far below the leaderboard floor, so the worth-it grade is capped at C+; the derived value lands at D. About $20 a month at studied doses. Derived from the October 2026 worth-it model.
Typical cost
$15-25/month
Common form, not a brand recommendation
Dosage context established
Studies used 200 to 300 mg/day, often in combination products that confound attribution. Half-life appears longer than caffeine's. Nothing about dose-response in humans is established beyond those two small programs.
Worth-it leaderboard
Theacrine sits outside the worth-it top 20.
Theacrine sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Short-term tolerability in the small trials was fine. As an adenosine-receptor-active stimulant-class compound, the prudent cautions mirror caffeine's (sleep timing, blood pressure, anxiety, pregnancy restraint) without caffeine's depth of safety data behind them. Unstudied in combination with other stimulants, its usual retail context.
Longevity Lab Report
Theacrine news. Graded when it happens.
The grade on this page stays free. The email carries the news on theacrine: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from the small human trial file in full. Theacrine's marketing borrows caffeine's credibility by chemical resemblance; this library grades compounds on their own human data, and by that standard the resemblance is doing all the work.
- 2026-10-23|Not listed under any goal: subjective-only findings from one small program do not carry a goal tag.
The week's longevity and biohacking news.
This grade for Theacrine rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.